Hepatitis A

Hepatitis A is a highly infectious virus that can cause inflammation of the liver. The virus is usually transmitted through food or water contaminated by human faeces or by direct contact with an infectious person. Hepatitis A is rare in the UK with most cases occurring in travellers who have recently visited countries where the disease is common.

Areas with high levels of infection include low-income countries that may have relatively poor sanitary conditions and hygiene practices. These areas include: the Indian subcontinent, Sub-Saharan and North Africa, parts of the Far East, South and Central America, and the Middle East.

Certain travellers are at increased risk of acquiring hepatitis A, including:

  • those who are staying with or visiting the local population
  • frequent and/or long-stay travellers to areas where sanitation and food hygiene are likely to be poor
  • those with existing medical conditions such as liver disease or haemophilia
  • men who have sex with men
  • people who inject drugs
  • those who may be exposed to the virus through their work
  • those going to areas of hepatitis A outbreaks who have limited access to safe water and medical care

Symptoms are often mild or absent in young children, but the disease becomes more serious with advancing age.  Recovery can vary from weeks to months. Following hepatitis A illness, immunity is lifelong. Symptoms may include: fever, loss of appetite, jaundice (yellowing of the eyes and skin), malaise and nausea.


As the most common mode of infection in travellers is consumption of contaminated food or water, the risk of acquiring hepatitis A can be reduced by ensuring good personal hygiene and following advice on the prevention of food and water-borne diseases.

Hepatitis A vaccine

Several effective inactivated hepatitis A vaccines are available for travellers intending to visit areas where hepatitis A is common. Some of these vaccines are combined with either hepatitis B or typhoid.

Length of protection

The duration of protection from a completed course of hepatitis A vaccine can be expected to be at least 25 years and is probably indefinite. However, Public Health England recommend that until further evidence is available on persistence of protective immunity, a booster dose at 25 years is indicated for those at ongoing risk of hepatitis A. Specific advice should be sought for individuals with altered immune responses, for whom an earlier booster may be recommended.



The National Travel Health Network and Centre (NaTHNaC) is commissioned by Public Health England to provide health information for both healthcare professionals and travellers. Information is compiled by the NaTHNaC clinical and scientific team, and updated regularly. Further advice on health risks and disease outbreaks is available at www.travelhealthpro.org.

Date last reviewed: November 2015

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.